Spots Global Cancer Trial Database for refractory malignant solid neoplasm

Every month we try and update this database with for refractory malignant solid neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)	NCT04439227	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	NCT00939770	Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur...	Crizotinib Laboratory Biom... Pharmacological... Questionnaire A...	1 Year - 21 Years	Children's Oncology Group
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)	NCT04439344	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Binimetinib	18 Years -	National Cancer Institute (NCI)
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	NCT02867592	Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor	Cabozantinib Cabozantinib S-... Pharmacological...	2 Years - 30 Years	National Cancer Institute (NCI)
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)	NCT04439149	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	PI3K-beta Inhib...	18 Years -	National Cancer Institute (NCI)
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations	NCT04233567	Advanced Malign... Cholangiocarcin... Metastatic Mali... Refractory Mali...	Infigratinib	18 Years -	Ohio State University Comprehensive Cancer Center
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors	NCT03878095	Malignant Solid... Refractory Chol... Refractory Mali...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Ceralasertib Computed Tomogr... Magnetic Resona... Olaparib	18 Years -	National Cancer Institute (NCI)
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	NCT04439318	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)	NCT04439240	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas...	FGFR Inhibitor ...	18 Years -	National Cancer Institute (NCI)
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)	NCT04439344	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Binimetinib	18 Years -	National Cancer Institute (NCI)
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02975882	Childhood Solid... Recurrent Malig... Recurrent Prima... Refractory Mali... Refractory Prim...	Irinotecan Hydr... Laboratory Biom... Pharmacological... Sirolimus Album... Temozolomide	12 Months - 21 Years	Children's Oncology Group
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)	NCT06357988	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Echocardiograph... Radionuclide Im... Vismodegib	18 Years -	National Cancer Institute (NCI)
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)	NCT04439123	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Capivasertib	18 Years -	National Cancer Institute (NCI)
Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors	NCT04981691	Refractory Mali...	anti-MESO CAR T...	18 Years - 80 Years	Ruijin Hospital
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors	NCT03878095	Malignant Solid... Refractory Chol... Refractory Mali...	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Ceralasertib Computed Tomogr... Magnetic Resona... Olaparib	18 Years -	National Cancer Institute (NCI)
FID-007 in Treating Participants With Advanced Solid Tumors	NCT03537690	Advanced Malign... Refractory Mali...	Laboratory Biom... PEOX-based Poly... Pharmacokinetic...	18 Years -	University of Southern California
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors	NCT06320405	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Axatilimab Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Paclitaxel Positron Emissi... Retifanlimab	18 Years -	OHSU Knight Cancer Institute
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	NCT02079740	Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Navitoclax Positron Emissi... Trametinib	18 Years -	National Cancer Institute (NCI)
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02159989	Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So...	Sapanisertib Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	NCT03220035	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor	Laboratory Biom... Vemurafenib	12 Months - 21 Years	National Cancer Institute (NCI)
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	NCT04439357	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas	NCT05053971	Advanced Lympho... Advanced Malign... Advanced Pancre... B-Cell Non-Hodg... Metastatic Panc... Refractory B-Ce... Refractory Lymp... Refractory Mali... Refractory Panc... Refractory T-Ce... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa...	BET Bromodomain... Core Biopsy Entinostat	18 Years -	National Cancer Institute (NCI)
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification	NCT03253679	Advanced Malign... Refractory Mali...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	NCT02323880	Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli...	Pharmacological... Selinexor	12 Months - 21 Years	Children's Oncology Group
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02780804	Brain Stem Neop... Pineal Region N... Recurrent Lymph... Recurrent Malig... Recurrent Prima... Recurrent Visua... Refractory Lymp... Refractory Mali... Refractory Prim... Refractory Visu...	Entinostat Laboratory Biom... Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03698994	Advanced Malign... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Refractory Soft... Wilms Tumor	Pharmacokinetic... Ulixertinib	12 Months - 21 Years	National Cancer Institute (NCI)
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations	NCT04233567	Advanced Malign... Cholangiocarcin... Metastatic Mali... Refractory Mali...	Infigratinib	18 Years -	Ohio State University Comprehensive Cancer Center
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)	NCT06390826	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Sunitinib	18 Years -	National Cancer Institute (NCI)
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)	NCT04439175	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Taselisib	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	NCT01709435	Recurrent Malig... Recurrent Melan... Recurrent Prima... Recurrent Thyro... Refractory Mali... Refractory Prim... Thyroid Gland M...	Cabozantinib S-... Laboratory Biom... Pharmacological...	2 Years - 18 Years	National Cancer Institute (NCI)
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	NCT04119024	Metastatic Mali... Metastatic Mela... Pathologic Stag... Pathologic Stag... Recurrent Malig... Refractory Mali... Uveal Melanoma Acral Melanoma Neuroendocrine ... Paraganglioma Pheochromocytom... Adrenocortical ... Pancreatic Neur... Thyroid Cancer Breast Cancer Lung Adenocarci... Head and Neck S...	Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Pho... Fludeoxyglucose... IL13Ralpha2-spe... Magnetic Resona... Positron Emissi...	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)	NCT04439149	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	PI3K-beta Inhib...	18 Years -	National Cancer Institute (NCI)
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)	NCT06400225	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Ulixertinib	18 Years -	National Cancer Institute (NCI)
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)	NCT04439331	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Defactinib Hydr...	18 Years -	National Cancer Institute (NCI)
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas	NCT03925428	Advanced Lympho... Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Refractory B-Ce... Refractory Lymp... Refractory Mali... Refractory Panc... Refractory T-Ce... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa...	Entinostat Molibresib	12 Years -	National Cancer Institute (NCI)
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)	NCT06400225	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Ulixertinib	18 Years -	National Cancer Institute (NCI)
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)	NCT04439201	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali...	Palbociclib	18 Years -	National Cancer Institute (NCI)
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors	NCT03320330	Recurrent Malig... Recurrent Osteo... Refractory Mali... Refractory Oste...	Laboratory Biom... Pepinemab Pharmacological...	12 Months - 30 Years	Children's Oncology Group
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)	NCT04439279	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer	NCT02671890	Metastatic Panc... Refractory Mali... Stage IV Pancre...	Chemotherapy Disulfiram Gemcitabine Hyd... Laboratory Biom...	18 Years -	Mayo Clinic
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)	NCT04439240	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas...	FGFR Inhibitor ...	18 Years -	National Cancer Institute (NCI)
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	NCT00939770	Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur...	Crizotinib Laboratory Biom... Pharmacological... Questionnaire A...	1 Year - 21 Years	Children's Oncology Group
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)	NCT06400264	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Nivolumab Relatlimab	18 Years -	National Cancer Institute (NCI)
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors	NCT03756818	Advanced Malign... Ovarian Carcino... Refractory Mali... Refractory Ovar...	Mivavotinib Paclitaxel Pharmacokinetic...	18 Years -	M.D. Anderson Cancer Center
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)	NCT04439175	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Taselisib	18 Years -	National Cancer Institute (NCI)
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment	NCT05455606	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Best Practice Chart Abstracti... Educational Int... Genomic Profile Interview Questionnaire A... Tumor Board Rev...	18 Years -	SWOG Cancer Research Network
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	NCT02079740	Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Navitoclax Positron Emissi... Trametinib	18 Years -	National Cancer Institute (NCI)
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)	NCT06400251	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors	NCT05098405	Advanced Malign...	MP0317, a tri-s... MP0317, a tri-s...	18 Years -	Molecular Partners AG
AOH1996 for the Treatment of Refractory Solid Tumors	NCT05227326	Refractory Mali...	PCNA Inhibitor ...	18 Years -	City of Hope Medical Center
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)	NCT04439227	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)	NCT06360575	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Crizotinib Radiologic Exam...	-	National Cancer Institute (NCI)
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer	NCT02671890	Metastatic Panc... Refractory Mali... Stage IV Pancre...	Chemotherapy Disulfiram Gemcitabine Hyd... Laboratory Biom...	18 Years -	Mayo Clinic
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)	NCT04439110	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Trastuzumab Emt...	18 Years -	National Cancer Institute (NCI)
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)	NCT06308822	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Erdafitinib Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors	NCT03784677	Advanced Malign... Refractory Mali... Refractory Ovar... Refractory Panc... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Ovari... Stage III Pancr... Stage III Prost... Stage IIIA Ovar... Stage IIIA Pros... Stage IIIB Ovar... Stage IIIB Pros... Stage IIIC Ovar... Stage IIIC Pros... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IVA Ovari... Stage IVA Prost... Stage IVB Ovari... Stage IVB Prost...	TRPV6 Calcium C...	18 Years -	M.D. Anderson Cancer Center
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02159989	Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So...	Sapanisertib Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	NCT04439292	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Dabrafenib Mesy... Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	NCT03213678	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Malignant Gliom... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor	Biospecimen Col... Computed Tomogr... FDG-Positron Em... Magnetic Resona... Samotolisib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	NCT04320888	Hematopoietic a... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Lymph... Recurrent Malig... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent WHO G... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Lymp... Refractory Mali... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory WHO ... Wilms Tumor	Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Selpercatinib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)	NCT04439253	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Crizotinib	18 Years -	National Cancer Institute (NCI)
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)	NCT04439201	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali...	Palbociclib	18 Years -	National Cancer Institute (NCI)
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	NCT03220035	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor	Laboratory Biom... Vemurafenib	12 Months - 21 Years	National Cancer Institute (NCI)
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	NCT05111561	Advanced Malign... Metastatic Mali... Refractory Mali... Triple-Negative... Unresectable Ma...	BET Bromodomain... Binimetinib Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease	NCT05791448	Advanced Cholan... Advanced Hepato... Advanced Malign... Metastatic Mali... Refractory Mali... Stage III Hepat... Stage IV Hepato...	Biospecimen Col... Computed Tomogr... Magnetic Resona... RNA Transcripti...	18 Years -	University of Southern California
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)	NCT06357975	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Crizotinib Radiologic Exam...	18 Years -	National Cancer Institute (NCI)
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)	NCT06303167	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Echocardiograph... Multigated Acqu... Osimertinib Radiologic Exam...	18 Years -	National Cancer Institute (NCI)
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)	NCT06390839	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Palbociclib	18 Years -	National Cancer Institute (NCI)
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies	NCT03217747	Advanced Malign... Castration-Resi... Malignant Solid... Metastatic Mali... Metastatic Pros... Prostate Carcin... Refractory Mali... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Avelumab Ivuxolimab Radiation Thera... Utomilumab	18 Years -	M.D. Anderson Cancer Center
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer	NCT04294628	Advanced Malign... HER2-Positive B... Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03698994	Advanced Malign... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Refractory Soft... Wilms Tumor	Pharmacokinetic... Ulixertinib	12 Months - 21 Years	National Cancer Institute (NCI)
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)	NCT04439136	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Afatinib Dimale...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study	NCT04500548	Constitutional ... Hematopoietic a... Lynch Syndrome Recurrent Lymph... Recurrent Malig... Recurrent Neuro... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Neur... Refractory Prim... Xeroderma Pigme...	Biospecimen Col... Ipilimumab Nivolumab	12 Months - 25 Years	National Cancer Institute (NCI)
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02780804	Brain Stem Neop... Pineal Region N... Recurrent Lymph... Recurrent Malig... Recurrent Prima... Recurrent Visua... Refractory Lymp... Refractory Mali... Refractory Prim... Refractory Visu...	Entinostat Laboratory Biom... Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)	NCT06390839	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Palbociclib	18 Years -	National Cancer Institute (NCI)
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03213691	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim...	Laboratory Biom... Selumetinib Selumetinib Sul...	12 Months - 21 Years	National Cancer Institute (NCI)
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma	NCT03323034	Recurrent Lymph... Recurrent Malig... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Prim...	Irinotecan Pevonedistat Temozolomide	6 Months - 21 Years	Children's Oncology Group
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors	NCT05071209	Recurrent Alveo... Recurrent Ewing... Recurrent Lymph... Recurrent Malig... Refractory Alve... Refractory Ewin... Refractory Lymp... Refractory Mali...	Elimusertib	12 Months - 30 Years	National Cancer Institute (NCI)
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)	NCT06385496	Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Sapanisertib	18 Years -	National Cancer Institute (NCI)
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)	NCT04439136	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Afatinib Dimale...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: